Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 8/20 | 0.39 |
| ▸ | PLG | P00747 | 8/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 8/20 | 0.37 |
| ▸ | F10 | P00742 | 6/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | PROC | P04070 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288985 | 0.78 | MMP13 (0.35) | ALDH1A1 | |
| SCHEMBL6289011 | 0.73 | PHGDH (0.44) | PTGER4ALDH1A1 | |
| SCHEMBL6289388 | 0.70 | ALDH1A1 (0.46) | ALDH1A1 | |
| SCHEMBL6288888 | 0.69 | CNR2 (0.43) | PTGER4ALDH1A1HPGD | |
| SCHEMBL6702268 | 0.69 | MMP13 (0.51) | PTGER4 | |
| SCHEMBL6292189 | 0.69 | POLB (0.46) | PTGER4ALDH1A1HPGD | |
| SCHEMBL6289329 | 0.68 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL6288949 | 0.67 | PHGDH (0.42) | PTGER4ALDH1A1 | |
| SCHEMBL6292163 | 0.67 | PHGDH (0.44) | PTGER4 | |
| SCHEMBL22768845 | 0.64 | GPR84 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | F2 169/4885PLG 356/4885KLKB1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.